Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 190 results

NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)

PAR
Wednesday, July 29, 2020
Monday, July 24, 2023
UG3/UH3
PAR-20-285

Funding Opportunity Purpose

This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional)

RFA
Wednesday, July 29, 2020
Tuesday, October 20, 2020
P50
RFA-AR-21-008

Funding Opportunity Purpose

Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers

Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)

PAR
Tuesday, July 28, 2020
Thursday, July 20, 2023
R01
PAR-20-254

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional)

PAR
Tuesday, July 28, 2020
Thursday, July 20, 2023
R21
PAR-20-255

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

The NINDS Human Biospecimen and Data Repository (U24 Clinical Trial Not Allowed)

RFA
Tuesday, July 28, 2020
Wednesday, October 21, 2020
U24
RFA-NS-20-031

Funding Opportunity Purpose

The National Institute of Neurological Disorders and Stroke (NINDS) is soliciting applications for a Human Biospecimen and Data Repository for Biomarkers Research ("Biomarkers Repository") in Neurological Disorders. Collaborative teams combining expertise in neuroscience, biomarkers, biospecimen handling, and data management are encouraged. Experience in biomarker research, such as evaluation of batch effects, protocol development, and analyte quality control measures, is expected. Successful applications will include a detailed description of 1) Administrative Structure, 2) Research and Resource Plan, and 3) Data Management and Web-Based activities.

BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed)

RFA
Friday, July 17, 2020
Saturday, October 15, 2022
U01
RFA-DA-21-006

Funding Opportunity Purpose

The purpose of this FOA isto develop tools and technologies to conduct cientifically rigorous, ethical, efficient, and cost-effective research infrastructure that supports germline and somatic transgenic and gene editing studies in the common marmoset (Callithrix jacchus). These studies should to answer crucial scientific questions that require genetic perturbation in a non-human primate model organism with the aim of supporting BRAIN goals of understanding the brain in health an disease.

NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)

RFA
Wednesday, July 15, 2020
Tuesday, September 27, 2022
P50
RFA-NS-21-001

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. The overarching goal of the specialized Udall Centers program is to establish a network of Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinsons disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Udall Centers also serve as local resources by organizing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community. Applicants are expected to identify and address an overall research theme that defines a critical challenge in PD research. The stated theme, proposed research projects, and associated cores will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the identified PD research challenge. Requirements include 1) a minimum of three research projects; 2) research cores that are each essential to accomplish the aims of at least two proposed research projects, plus an Administrative Core; 3) a mission statement and plan for career enhancement of Center trainees and investigators; and 4) a plan for effective outreach, including dissemination of Udall Center research results, to the local patient and advocacy community. The NINDS Udall Centers program prioritizes innovative and integrative research with significant potential for discovery. A considerable degree of synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. The Udall Center Director (PD/PI) must be an established leader in scientific research with visionary leadership skills and proven expertise.

NINDS Morris K. Udall Parkinson's Disease Research Center Without Walls (P20 Clinical Trial Optional)

RFA
Wednesday, July 15, 2020
Tuesday, September 29, 2020
P20
RFA-NS-21-002

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) requests Exploratory Grant (P20) applications for the planning and initiation of collaborative activities to advance Parkinson's Disease (PD) research. The goal of this FOA is to convene new transdisciplinary research consortia and formalize the multi-institutional organizational and investigational structure necessary to resolve an essential challenge in Parkinson's disease (PD) through a subsequent NINDS Udall Center without Walls (CWOW) approach. The most compelling applications will: (i) identify a fundamental PD research priority; (ii) build an exemplary research consortium; (iii) gather supportive preliminary data; and (iv) demonstrate exceptional potential to pursue a targeted strategy to remove a critical impediment blocking advancement of the understanding and treatment of PD. The stated challenge and related research feasibility projects will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the central PD research challenge. To foster the development of innovative research collaborations, this FOA will provide support for new research consortia only; continuation of established projects and teams will not be supported. Proposed consortia must include the optimal combination of specialized expertise required to resolve the stated challenge using a goal-driven approach. The Program Director/Principal Investigator (PD/PI) must be eminently qualified to provide visionary scientific leadership and effective oversight of consortium administrative activities. Participating investigators should be recognized as world-class experts in their fields. Teams must be anchored by at least one PD researcher. To maximize potential for new insights and incorporation of cutting-edge approaches, consortia will actively integrate at least one investigator with primary expertise in another, complementary research area. The applicant inst

PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

PA
Tuesday, July 14, 2020
Tuesday, April 6, 2021
R41/R42
PA-20-265

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

PHS 2020-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

PA
Tuesday, July 14, 2020
Tuesday, April 6, 2021
R43/R44
PA-20-260

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

Pages